Studies in animals and humans suggest a role for peptide YY in regulating satiety.
The physiologic role of PYY3-36, however, has not been investigated in detail.
Dr Christoph Beglinger and colleagues examined peptide YY release in response to 2 meals.
The 2 meals differed in their calorie content and the research team related the plasma levels to those obtained after exogenous infusion.
In a second step, the effect of graded intravenous doses of synthetic human peptide YY3-36 on food intake was investigated in healthy male volunteers.
The research team conducted a double-blind, placebo-controlled study.
|There was a 32% reduction in calorie intake after graded peptide YY infusions|
The team found that plasma peptide YY concentrations increased in response to food intake reflecting the size of the calorie load.
Graded peptideYY3-36 infusions resulted in a dose-dependent reduction in food intake, with a maximum inhibition of 35%.
The team noted a similar reduction in calorie intake after graded peptide YY infusions, of 32%.
Fluid ingestion was also reduced by 18% with peptide YY.
The researchers found that nausea and fullness were the most common side effects produced by peptide YY, especially at the highest dose.
In addition, subjects experienced less hunger and early fullness in the premeal period during peptide YY3-36 infusion at the highest dose.
Dr Beglinger's team commented, “This study shows that intravenous infusions of peptide YY3-36 decrease spontaneous food intake.”
“The inhibition is, however, only significant at pharmacologic plasma concentrations.”
“Whether peptide YY3-36 has a physiologic role in the regulation of satiety in humans remains to be defined.”